FGD2

Across TCGA pan-cancer cohorts, FGD2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FGD2 data layer compared with 28 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FGD2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FGD2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, CCRCC, and LSCC are the cancer types where FGD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.762	0.516	.007	7	view →
CCRCC	DFS	Quartile	III,IV	0.614	1.000	.024	7	view →
LSCC	DFS	Tertile	II,III,IV	0.556	0.878	.029	5	view →
PDAC	OS	Tertile	II,III,IV	0.729	0.496	.021	4	view →
UCEC	DFS	Median	All	0.926	1.000	.020	2	view →
GBM	OS	Quartile	All	0.256	0.519	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FGD2–LUAD (DFS)

Open the LUAD breakdown →